U.S. Markets closed

Endurance RP Limited (0575.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
0.171+0.002 (+1.18%)
At close: 3:59PM HKT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.169
Open0.168
Bid0.168 x 0
Ask0.172 x 0
Day's Range0.166 - 0.171
52 Week Range0.107 - 0.290
Volume1,487,675
Avg. Volume1,835,434
Market Cap410.301M
Beta (5Y Monthly)0.30
PE Ratio (TTM)N/A
EPS (TTM)-0.021
Earnings DateMar 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateFeb 08, 2013
1y Target EstN/A
  • PR Newswire

    Endurance RP Limited (Stock Code: 0575.HK) Announces 2021 Interim Results

    Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a Hong Kong-based investment company specializing in growth and value-led investments in the healthcare and late-stage life science sector, is pleased to announce the unaudited consolidated interim results for the 6 months ended 30 June 2021 ("Reviewing Period").

  • PR Newswire

    Endurance Longevity Announces Positive Profit Alert for Interim Results 2021 and Other Exciting Business Updates

    Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce a positive profit alert for the interim results 2021 for the six month period ended 30 June 2021. The alert was followed by positive market reaction with the share price up by 18.7% to an intra-day high of HK$0.184 on the following day. The Company expects profit attributable to shareholders for the six months ended 30 June 2021 will reach ap

  • PR Newswire

    Fortacin™ Receives Extremely Encouraging Assessment in US Market Research Analysis

    Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce that Fortacin™, a European, Hong Kong and Macau approved treatment for PE receives a detailed market assessment by MME, one of the leading global market research companies for health care in the United States.